Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2020

Open Access 01.12.2020 | Research article

BMI differences among in-hospital management and outcomes in patients with atrial fibrillation: findings from the Care for Cardiovascular Disease project in China

verfasst von: Fuxue Deng, Yan Zhang, Qiang Zhao, Yangyang Deng, Shanshan Gao, Lisha Zhang, Mengya Dong, Zuyi Yuan, Xinjun Lei, on behalf of the CCC-AF investigators

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2020

Abstract

Background

Underweight or obese status influences the prognosis of atrial fibrillation (AF). However, the association between stratification of body mass index (BMI) and in-hospital outcomes in patients with AF, remains lacking in China.

Methods

Using data from the Improving Care for Cardiovascular Disease in China-AF project, which was launched in February 2015 and recruited 150 hospitals in China, we compared characteristics, in-hospital treatments and clinical outcomes among the stratifications of BMI for Asians.

Results

A total of 15,867 AF patients with AF were enrolled, including 830 (5.23%) underweight, 4965 (31.29%) with normal weight, 3716 (23.42%) overweight, 5263 (33.17%) obese class I and 1093 (6.89%) obese class II participants. Compared with normal weight patients, underweight, overweight, and obese patients showed increased percentages of CHADS2 scores (3–6) and CHA2DS2-VASc scores (5–9). During hospitalization, overweight or obese patients showed greater use of rhythm control medications, anticoagulant drugs, and intervention therapies than underweight–normal weight patients. In adjusted logistic models, BMI was a strong predictor of in-hospital mortality. Especially, underweight BMI was associated with higher incidence of in-hospital mortality, with an adjusted odds ratio of 2.08 (95% confidence interval, 1.56–4.46; p = 0.04) than overweight and obese BMI.

Conclusions

Asian patients with AF and high BMI received more medical treatments and presented less adverse in-hospital outcomes compared with those with underweight–normal weight. Although low BMI may be associated with other comorbidities and advanced age, underweight BMI retained a negative correlation with all-cause mortality in the patients with AF during hospitalization.
Hinweise

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12872-020-01544-8.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AF
Atrial fibrillation
BMI
Body mass index
CAD
Coronary artery disease
CHF
Chronic heart failure
CCB
Calcium channel blocker
CCC-AF project
Care for cardiovascular disease in China- atrial fibrillation project
CI
Confidence interval
NOAF
New-onset atrial fibrillation
NVAF
Nonvalvular atrial fibrillation
OR
Odds ratio
PNI
Prognostic nutritional index
ROS
Reactive oxygen species

What is new?

  • This multicenter population-based cohort from 150 hospitals distributed throughout almost all regions of China is the largest contemporary registry study that explored BMI–related differences in clinical characteristics, management, and outcomes of patients with atrial fibrillation (AF).
  • Patients with BMI > 23 in China required more frequent oral medical treatments and intervention strategies and presented lower in-hospital mortality rate than normal–underweight patients.

What are the clinical implications?

  • The quality of care for low–BMI patients hospitalized for AF in China should be improved using evidence-based treatments and strategies for prevention.
  • Low BMI patients exhibit poorer in-hospital mortality compared with normal–weight or overweight patients. Thus, improving weight management may aid in reducing the observed weight differences in in-hospital mortality.
  • The association between abdominal obesity and fat distribution with AF in China must be further investigated.

Background

Atrial fibrillation (AF) is the most common sustained arrhythmia and resulted in high prevalence of stroke, all-cause mortality, and heart failure [1]. Both Asian populations and Western countries encounter increasing numbers of new-onset AF (NOAF), which is affected by several demographic and clinical risk factors, including age, male sex, obesity, and the presence of coronary artery disease (CAD) [2]. By 2050, the estimated number of patients with AF will reach 72 million, and almost 3 million may experience AF-associated stroke [3].
In China, limited studies have assessed the association between body weight/body mass index (BMI) and the quality of care and outcomes among patients with AF. Contemporary evidence in 2017 [4] from Korea proved that abdominal obesity is a potential modifiable risk factor for AF in non-obese Asian individuals. Similar results were observed in a population of young women from Denmark [5], suggesting that interventions to decrease abdominal obesity may reduce the population burden of AF. Furthermore, in Korean research, being underweight is associated with biological effects that contribute to AF development [6]. However, few studies have systematically compared the clinical characteristics and treatments of patients with AF according to BMI stratification in the current year. The relation of BMI and in-hospital quality of care to poor short-term outcomes in patients with AF in China remains unclear.
To avoid the limited representativeness of hospitals and shortage of quality control in previous studies launching the clinical practice of AF in China [7, 8], the Chinese Society of Cardiology (CSC) and the American Heart Association (AHA) initiated the Improving Care for Cardiovascular Disease in China (CCC)-AF project. The CCC-AF was developed on the basis of the guideline initiative of AHA [9]. Using data from this timely feedback database, we performed a population-based evaluation to investigate BMI differences in clinical characteristics, management during hospitalization and discharge, and in-hospital mortality among patients hospitalized for AF.

Method

Study population

Patients with established or newly diagnosed AF and who visited one of 150 tertiary hospitals from 30 provinces were recruited. Every tertiary hospital included in the CCC-AF project has at least 120 patients with a primary diagnosis of AF annually [10]. Exclusion criteria comprised patients with AF due to reversible conditions (e.g., untreated thyroid disease and pulmonary embolism) and with no record of BMI. In accordance with the exclusion criteria above, we analyzed data from 15,867 patients from February 2015 to March 2017 with an AF diagnosis (International Classification of Diseases, Ninth Revision [ICD-9]: 427.31; ICD, Tenth Revision [ICD-10]: I48.0%, I48.2%, I48.91%) before or upon admission. The CCC-AF project was registered at www.​ClinicalTrials.​gov (Trial registration number: NCT02309398) with the official title “Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC-Atrial Fibrillation”. It is an observational case-control and retrospective study that started in January 2015.

Data collection

Baseline characteristics and clinical data were collected in accordance with the American College of Cardiology (ACC)/AHA recommendations [11] on data standards for clinical research on AF. Using Oracle Clinical Remote Data Capture system (Oracle Corporation, Redwood City, CA, USA) and a web-based platform, participating instructions were informed to submit consecutive eligible patients. Four third-party clinical approaches were used to monitor the accuracy and completeness of data collection. The supervision approaches consisted of face-to-face training workshops prior to data entry, a standardized online reporting tool, on-site quality control from a third party, and monthly inspections for data completeness as a monthly report. Details of the design, methodology, and quality control of CCC-AF project were published [10]. The objectives of the program include understanding of the current situation and main problems for the management of inpatients with AF, the assessment of the performance of the current quality improvement strategy, and the exploration and refinement of an optimal approach to promote clinical management. As a collaborative project of the CSC and AHA, the CCC-AF project is conducted by the Beijing Institute of Heart, Lung, and Blood Vessel Diseases from Beijing Anzhen Hospital. Being one of the participating hospitals in CCC-AF project, under the permission from host unit of Ethics Committee of Beijing Anzhen Hospital and our hospital, oral consent was obtained at the beginning of data collection instead of the formal one. Furthermore, data use, analysis and implementation of this study were agreed by host unit of Beijing Anzhen Hospital with signing formal consent.

Definitions

Patients were diagnosed if AF or atrial flutter was presented on an electrocardiogram during admission or obtained from a hospital or physician chart. Every electrocardiographic record of AF was confirmed by at least two cardiologists. Identification of nonvalvular (NVAF) and valvular AF was based on CCS and ACC/AHA/Heart Rhythm Society guidelines [12]. Height and weight were measured using standardized protocol on admission. BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m2). All patients were categorized into five groups according to BMI following the World Health Organization recommendations for Asians: underweight, < 18.5 kg/m2; normal range, 18.5–22.9 kg/m2; overweight, 23.0–24.9 kg/m2; obese class I, 25.0–29.9 kg/m2; and obese class II, ≥30.0 kg/m2 [13]. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg upon the records of ambulatory blood pressure monitoring and blood pressure measurement in at least three successive days, or having a history of hypertension or receiving antihypertensive therapy. Diabetes mellitus was considered on the basis of history records or the intake of glucose-lowering drugs. Chronic heart failure (CHF), stroke, renal failure, rheumatic heart disease, chronic obstructive pulmonary disease, and cancer were all defined as self-reported medical history. CHADS2 and ChA2DS2-VASc scores are associated with an increased risk of stroke and death in patients with AF, and they also play predictive roles in clinical anticoagulant use. CHADS2 score (range: 0–6) includes congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, and previous stroke/transient ischemic attack (double weight), which is the most commonly used parameter for stratifying stroke risk. CHA2DS2-VASc score (range: 0–9) adds items of vascular disease, age 65–74 years, (female) sex category based on CHADS2, and an alternative scoring of age with double weight to age ≥ 75 years [14].

Statistical analysis

Basic information, medical procedure, and in-hospital outcomes of patients were described according to the BMI categories. Continuous variables were shown as mean ± standard deviation or median with 25th and 75th percentiles, whereas categorical variables were presented as count and percentages. Continuous or categorical variables were compared using unpaired t-test or one-way ANOVA test and χ2 test, respectively. The association between BMI and in-hospital outcomes was detected and further adjusted using binary logistic regression, which included age, sex, CHADS2 score, CHA2DS2-VAS score, heart failure history, stroke history, hypertension, and diabetes mellitus as adjusted variables. All p values were two-tailed, and p < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 23.0 (IBM) software.

Results

Baseline characteristics

Table 1 provides the baseline characteristics obtained for the study. Among the 15,867 patients with AF, the percentage of underweight, normal weight, overweight, obese class I, and obese class II individuals accounted for 5.2, 31.3, 23.4, 33.2, and 6.9%, respectively. Compared with those with normal weight, patients with higher BMI were younger and more exposed to smoke and drinking. Patients with higher BMI presented more history of hypertension and diabetes mellitus, whereas patients who were underweight previously suffered from CHF, renal failure, chronic obstructive pulmonary disease (COPD), and cancer. Furthermore, patients with low and high BMI presented higher CHADS2 scores (3–6) and CHA2DS2-VAS scores (5–9) compared with those with normal weight, respectively. Interestingly, overweight–obese AF patients had greater use of oral medications, including rhythm control drugs and anticoagulants, before admission than underweight–normal weight patients.
Table 1
Clinical characteristics of patients with AF on admission
Variables
Total
N = 15,867
Underweight
BMI < 18.5
(n = 830)
Normal
18.5 ≤ BMI < 23
(n = 4965)
Overweight
23 ≤ BMI < 25
(n = 3716)
Obese, class I
25 ≤ BMI < 30
(n = 5263)
Obese, class II
BMI ≥ 30
(n = 1093)
p value
Age
68.09 ± 11.93
72.42 ± 12.69
69.46 ± 12.01
68.11 ± 11.65
66.62 ± 11.57
65.64 ± 11.90
< 0.001
Male
8860 (55.8)
352 (42.4)
2610 (52.6)
2158 (58.1)
3189 (60.6)
551 (50.4)
< 0.001
Current smoker
3421 (21.6)
147 (17.7)
990 (19.9)
764 (20.6)
1291 (24.5)
229 (21.0)
< 0.001
Current drinking
1808 (11.4)
60 (7.2)
476 (9.6)
412 (11.1)
722 (13.7)
138 (12.6)
< 0.001
Comorbidities
 Hypertension
8504 (53.6)
296 (35.7)
2306 (46.4)
1954 (52.6)
3205 (60.9)
743 (68.0)
< 0.001
 Diabetes mellitus
2712 (17.1)
68 (8.2)
641 (12.9)
666 (17.9)
1064 (20.2)
273 (25.0)
< 0.001
 CAD
3667 (23.1)
180 (21.7)
1073 (21.6)
909 (24.5)
1236 (23.5)
269 (24.6)
0.012
 CHF
2194 (13.8)
171 (20.6)
747 (15.0)
500 (13.5)
642 (12.2)
134 (12.3)
< 0.001
 Stroke
2024 (12.8)
113 (13.6)
628 (12.6)
489 (13.2)
658 (12.5)
136 (12.4)
0.820
 Renal failure
396 (2.4)
39 (4.7)
129 (2.6)
81 (2.2)
130 (2.5)
17 (1.6)
< 0.001
 Underwent dialysis
22 (5.5)
2 (5.1)
10 (7.8)
3 (3.7)
6 (4.6)
1 (5.9)
0.002
 Renal transplant
7 (1.8)
0 (0)
3 (2.3)
0 (0)
4 (3.1)
0 (0)
0.001
 Rheumatic heart disease
887 (5.6)
105 (12.7)
386 (7.8)
198 (5.3)
169 (3.2)
29 (2.7)
< 0.001
 COPD
613 (3.9)
57 (6.9)
202 (4.1)
132 (3.6)
179 (3.4)
43 (3.9)
< 0.001
 Cancer
260 (1.6)
27 (3.3)
105 (2.1)
61 (1.6)
55 (1.0)
12 (1.1)
< 0.001
 First diagnosis of AF
1609 (10.1)
84 (10.1)
482 (9.7)
403 (10.8)
545 (10.4)
95 (8.7)
< 0.001
 Non-valvular AF
13,792 (86.9)
610 (73.5)
4106 (82.7)
3265 (87.9)
4796 (91.1)
1015 (92.9)
< 0.001
On admission value
 HR at rest (bmp/min)
88.64 ± 27.68
93.45 ± 29.77
88.57 ± 27.90
88.05 ± 27.92
87.87 ± 26.85
91.03 ± 27.35
< 0.001
 SBP (mmHg)
130.57 ± 20.45
123.69 ± 21.04
128.50 ± 20.57
130.50 ± 20.47
132.64 ± 19.85
135.45 ± 19.81
< 0.001
 DBP (mmHg)
78.82 ± 13.33
74.11 ± 13.52
77.10 ± 13.12
78.69 ± 13.15
80.46 ± 13.21
82.74 ± 13.20
< 0.001
 QTc (ms)
419.22 ± 64.13
416.15 ± 60.39
418.82 ± 65.16
417.48 ± 61.78
419.31 ± 62.92
428.15 ± 59.31
0.003
 LVEDd (ms)
49.99 ± 8.18
48.26 ± 9.41
49.75 ± 8.71
49.82 ± 8.02
50.36 ± 7.74
51.00 ± 7.18
< 0.001
 LAAP (mm)
42.73 ± 9.11
43.42 ± 11.75
42.39 ± 9.46
42.11 ± 9.21
43.02 ± 8.33
44.28 ± 8.46
< 0.001
LVEF
      
< 0.001
  < 40%
1151 (7.3)
77 (9.3)
421 (8.5)
241 (6.5)
338 (6.4)
74 (6.8)
 40–49%
1463 (9.2)
95 (11.4)
468 (9.4)
354 (9.5)
450 (8.6)
96 (8.8)
  ≥ 50%
13,253 (83.5)
658 (79.3)
4076 (82.1)
3121 (84.0)
4475 (85.0)
923 (84.4)
CHADS2score
      
0.001
 0–1
9541 (60.1)
489 (58.9)
3058 (61.6)
2265 (61.0)
3126 (59.4)
603 (55.2)
 2
3519 (22.2)
196 (23.6)
1088 (21.9)
773 (20.8)
1179 (22.4)
283 (25.9)
 3–6
2782 (17.5)
141 (17.0)
809 (16.3)
670 (18.0)
955 (18.1)
207 (18.9)
CHA2DS2-VAS score
      
< 0.001
 0–1
4646 (29.3)
184 (22.2)
1396 (28.1)
1101 (29.6)
1674 (31.8)
291 (26.6)
 2–4
9082 (57.2)
519 (62.5)
2937 (59.2)
2107 (56.7)
2881 (54.7)
638 (58.4)
 5–9
2114 (13.3)
123 (14.8)
622 (12.5)
500 (13.5)
705 (13.4)
164 (15.0)
Medication history
 Beta-blocker
4485 (28.3)
190 (22.9)
1289 (26.0)
1002 (27.0)
1633 (31.0)
371 (33.9)
< 0.001
 CCB
2361 (14.9)
76 (9.2)
601 (12.1)
500 (13.5)
982 (18.7)
202 (18.5)
< 0.001
 Antiarrhythmic agents
1404 (8.8)
35 (4.2)
378 (7.6)
329 (8.9)
540 (10.3)
122 (11.2)
< 0.001
 Antiplatelet agents
1137 (7.2)
48 (5.8)
351 (7.1)
286 (7.7)
359 (6.8)
93 (8.5)
0.094
 Warfarin
2097 (13.2)
118 (14.2)
653 (13.2)
509 (13.7)
668 (12.7)
149 (13.6)
0.127
 Aspirin
3302 (20.8)
114 (13.7)
952 (19.2)
786 (21.2)
1185 (22.5)
265 (24.2)
< 0.001
Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
AF indicates atrial fibrillation; BMI Body mass index; CAD Coronary artery disease; CCB Calcium channel blocker; CHF Chronic heart failure; COPD Chronic obstructive pulmonary disease; DBP Diastolic blood pressure; HR Heart rate; LAAP Left atrium diameter; LVEDd Left ventricular end-diastolic dimension; SBP systolic blood pressure; LVEF Left ventricular ejection fraction; QTc Corrected QT interval; CHADS2 score, congestive heart failure, hypertension, age 75 years of older, diabetes mellitus, prior stroke and TIA; CHA2DS2-VAS score, congestive heart failure, hypertension, age 75 years of older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65–74 years, female

Management during hospitalization and discharge

Disparities in medical treatments and intervention among patients with AF stratified by BMI were observed (Fig. 1). Patients with high BMI obtained advantage in the use of oral medications. Except that of aspirin, the use of beta-blocker, calcium channel blocker (CCB), antiarrhythmic agents, and antiplatelet agents during hospitalization was higher in obese and overweight groups than in normal and underweight groups. Moreover, overweight patients more likely received cardioversion or ablation than normal-weight patients, who presented more pacemaker implantations than overweight patients. In obese patients, 32.9% received cardioversion therapy (including medical and electrical cardioversion), whereas 2.1% underwent catheter ablation, approximately 3 times more than underweight patients (all p < 0.001, Fig. 1a.) More details of specific value can be found from Supplementary material (Sup Table 1).
Among patients with AF, prescription rates at discharge of oral medications according to recommendations all increased compared with those before admission. However, compared with normal-weight patients, patients with low BMI categories were less likely to receive CCB, antiarrhythmic agents and aspirin at discharge (Fig. 1b).

In-hospital outcomes

As illustrated in Fig. 2, worse in-hospital outcomes were observed in underweight patients than normal weight, overweight, and obese class I, including all-cause mortality (1.08% vs. 0.42, 0.35, and 0.21%, respectively, p = 0.003), cardiogenic shock (1.08% vs. 0.50, 0.54, and 0.23%, respectively, p = 0.006), and especially heart failure (23.97% vs. 16.60, 15.10, and 14.16%, respectively, p < 0.001). However, no statistical difference was observed in stroke (1.45% vs. 1.57, 1.16, and 1.44%, respectively, p = 0.343) among the groups. After adjustment for age and sex, underweight AF population showed higher risk of in-hospital mortality (adjusted odds ratio (OR), 2.29; 95% confidence interval (CI), 1.04–5.03; p = 0.03) than those who were overweight and obese class I (Fig. 3a). We further adjusted for hypertension, mellitus diabetes, stroke, heart failure, renal failure, rheumatic heart disease, COPD, and cancer, and BMI. Nevertheless, being underweight was still associated with higher incidence of in-hospital mortality (adjusted OR, 2.08; 95% CI, 1.56–4.60; p = 0.045) than being overweight and obese class I (Fig. 3b). Multivariable analyses indicated that AF patients with a history of heart failure (OR, 2.68; 95% CI, 1.61–4.98; p = 0.001), stroke (OR, 2.32; 95% CI, 1.29–4.01; p = 0.005), and rheumatic heart disease (OR, 2.98; 95% CI, 1.78–5.35); p = 0.006) and with age of ≥75 years (OR, 3.78; 95% CI, 1.21–9.35; p = 0.035) presented higher risk of in-hospital mortality.
As presented in Table 2, overweight patients with AF showed lower resting heart rate on discharge compared with underweight–normal patients. Interestingly, as the BMI increased, the length of stay during hospitalization reduced inversely. Although guidance on smoking, dietary patterns and weight management was provided to AF patients with slight bias to obese groups, a gap was still needed to increase changes in lifestyle and bad habits.
Table 2
Differences of clinical index and advisement among patients with AF on discharge
Variables
Total
N = 15,867
Underweight
BMI < 18.5
(n = 830)
Normal
18.5 ≤ BMI < 23
(n = 4965)
Overweight
23 ≤ BMI < 25
(n = 3716)
Obese, class I
25 ≤ BMI < 30
(n = 5263)
Obese, class II
BMI ≥ 30
(n = 1093)
p value
HR at rest (bmp/min)
76.24 ± 17.50
77.96 ± 20.04
76.69 ± 17.89
75.00 ± 16.47
76.26 ± 17.42
77.27 ± 17.46
0.002
Length of stay, days
9.17 ± 8.77
9.83 ± 6.96
9.27 ± 7.36
9.28 ± 12.21
8.98 ± 7.73
8.76 ± 6.13
0.031
Guidance on quitting smoking
3120 (19.7)
142 (17.1)
921 (18.5)
705 (19.0)
1147 (21.8)
205 (18.8)
< 0.001
Guidance on dietary patterns
14,157 (89.2)
741 (89.3)
4423 (89.1)
3304 (88.9)
4712 (89.5)
977 (89.4)
0.007
Weight management
11,032 (69.5)
497 (59.9)
3306 (66.6)
2583 (69.5)
3801 (72.2)
845 (77.3)
< 0.001
Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
AF indicates atrial fibrillation; BMI Body mass index; HR Heart rate

Discussion

In this large multicenter-based registry for hospitalized AF patients in China, patients who were underweight presented more history of CHF, renal failure, and cancer and higher scores of CHADS2 and CHA2DS2-VAS than obese participants. Furthermore, underweight patients (BMI < 18.5) were less likely to receive oral medications and cardiac intervention therapies than normal- weight and overweight individuals. The underweight group exhibited higher crude in-hospital death, heart failure, and cardiogenic shock rate than normal-weight or obese patients. After multivariable adjustment, underweight but not overweight patients with AF in China showed association with increased risk of in-hospital mortality, and low BMI prefer to co-morbidities and advanced age may be one of the possible explanations in our study.
Obesity features strong relationships not only with increased risk of NOAF [15] but also the subsequent progression of AF compared with normal weight [5, 16]. However, we observed an increased risk of in-hospital mortality among underweight patients with AF rather than obese ones in China. Underweight phenotype is suggested to be associated with the presence of cardiovascular disease (CVD) in ICD I00-I99 or a history of myocardial infarction [6, 17]. The worsened progression of disease may be caused by the generally low prescription rates during hospitalization and subsequent maintenance therapies after discharge. In this hospital-based study, the prescription rates, including those for aspirin, beta-blockers, antiplatelet agents, and CCB, from both hospitalization and discharge were lower in underweight participants than in normal- weight or obese groups. Similar to several studies, being underweight was associated with high frequency of chronic lung disease, malignancy, and perhaps thyroid disease [6, 17]. Comprehensive factors, including physical conditions, dietary status, and physical endurance of underweight patients may affect medical and intervention therapies from physicians.
Obesity is thought to be one of the risk factors responsible for incidence of CVD [18]. Interestingly, in patients with heart failure, CAD and AF, obesity is positively associated with better outcomes [1921]. In this study, obese class I (25 ≤ BMI < 30) was negatively associated with in-hospital mortality by using unadjusted binary regression model. However, it showed no relationship after adjustment for age, sex, and other clinical complications. Such finding is especially relevant as age is one of the major predictors of all-cause mortality among patients with AF [22]. From this aspect, the phenomenon is referred to as “obesity paradox” and the obesity mortality paradox in AF may be a true clinical case [23]. Several potential reasons are found for the paradoxical results of obesity in AF, including undesirable factors, such as the effect of comorbidities (hypertension, diabetes mellitus, obstructive sleep apnea syndrome etc.), pericardial fat deposits and highly metabolic active tissue, the influence of prevalent cardiac dysfunctions (ventricular adaptation, greater left atrial size etc.), and an increased activity of the sympathetic nervous system associated with obesity. The positive relationship between obesity and outcomes of AF was due to the ability of obesity-linked lipoproteins in blood to scavenge bacterial lipopolysaccharide, diminishing the effect of inflammatory process activity and the reducing effect of obesity on the blood concentration of atrial natriuretic peptide [24]. In this study, overweight and obese patients were younger, experienced more hypertension, and featured slightly higher left atrium diameter value and heart rate than those with underweight and normal weight. This result implies that underweight–normal-weight patients may exhibit lower metabolic reserves to counterbalance the increased catabolic stress of AF than obese patients.
The associations between underweight status and all-cause mortality may be explained as follows. Inflammation is more active and exists longer in obese patients than that in normal-weight or underweight population and results from chronic inflammatory conditions, including mediator production and interactions among cytokines and cells [25, 26]. To date, limited research identified these complicated elements or the abovementioned changes in the underweight population. Several studies on cancer reported that underweight always follow poor nutritional status, which is associated with increased toxicity and decreased response to anti-cancer therapy [27, 28]. By contrast, overweight and obese patients consistently maintain larger nutritional stores and have been shown to present significantly lower rates of treatment-related toxicity than underweight patients. However, underweight patients may include both undernourished and healthy individuals with a lean body type. Serum albumin, prognostic nutritional index (PNI), and hemoglobin levels were significantly lower in the underweight population than in others from a present study [29]. Concordant with other research [30], our study showed that underweight AF patients presented lower prescription rate and intervention therapies during hospitalization than those with normal weight or obesity, indicating the same trends as medicine usage on discharge. In general, compared with underweight AF patients, those belonging to high BMI categories benefit from younger age; fewer serious comorbidities, such as renal dysfunction or cancer; greater use of anticoagulants; and rhythm control therapies. However, increasing adipose tissues may become a relatively beneficial factor to obese patients. Adiponectin, which is produced by adipose tissue, exerts anti-inflammatory and cardioprotective effects, including in myocardial infarction and CAD [31]. Underweight patients present higher adiponectin levels than those with normal weight [32]. High adiponectin levels have been found to be associated with an increased risk of AF [33]. Regardless of adjustment, our study suggested that being underweight retained the negative correlation with all-cause mortality in patients with AF during hospitalization.

Limitations

Despite the strengths listed above, several limitations deserve to be mentioned. First, although BMI is conventionally thought to be associated with outcomes of AF, differences in body fat distribution are nowadays considered more important than calculated BMI alone. Waist circumference and waist-to-hip circumference ratio or pericardial fat value were excluded from this registry research, but they could have provided additional information. Second, AF was determined by registration data, and early recognition of AF and quantification of AF burden are aggravated by the often-silent nature of the rhythm disturbance (e.g., asymptomatic AF). Therefore, we cannot ensure that any asymptomatic or unrecognized AF existed before the patients were enrolled into the study. We could not analyze the subtypes of AF (including initial, paroxysmal, persistent, and permanent AF) separately. The subtypes and duration of disease could influence metabolic derangements, left ventricular hypertrophy, and subsequent progressive atrial dilatation. These conditions may also contribute to BMI-related outcomes and may become further prospective research interests. Third, as one of the highly complex arrhythmias, AF must be managed with a multidisciplinary integrated care approach, including primary care physicians, dieticians, endocrine specialists, sleep physicians, and exercise physiologists, to improve recommended therapies and cardiorespiratory fitness in underweight, overweight and obese subjects. Retrospective studies failed to analyze significant differences in weight change during follow-up on the basis of BMI. Studies referring to the association between weight management following dieticians and long-term outcomes among hospital-based AF patients are needed in the future. Fourth, the underweight patients with AF suffered from more comorbidities and advanced age than any other BMI-stratified patients. The high rate of comorbidities and age in underweight patients with AF may explain their high in-hospital mortality in our study. Therefore, further studies are required for specific enrolled patients with AF stratified by BMI. Finally, our cohort predominantly comprised Chinese patients. Thus, our findings may not apply to non-Asian individuals. Despite these limitations, our study provides important real-world data on the relationship between BMI and clinical outcomes in AF patients.

Conclusions

In this observational study, BMI and all-cause mortality in AF patients showed an inverse relationship. Underweight AF patients. Presented higher crude in-hospital death, heart failure, and cardiogenic shock rate than normal-weight or obese AF individuals. After multivariable adjustment, the possible causes of low BMI may associate with other comorbidities and advanced age. Underweight BMI in Chinese patients but not overweight status was associated with increased risk of in-hospital mortality.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12872-020-01544-8.

Acknowledgements

We acknowledge all 150 participating hospitals for their contributions to the CCC-AF project. Danmeng Liu (Department of Epidemiology and Health Statistics, Health Science Center, Xi’an Jiaotong University, Shaanxi, PR. China) and Fang Jia (Department of Infectious diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, PR. China) contributed largely to revision of the study protocol and permitted not to listed as co-authors.
Institutional Review Board approval was granted for this research by the Ethics Committee of Beijing Anzhen Hospital, Capital Medical University and the First Affiliated Hospital of Xi’an Jiaotong University. Under the permission from host unit of Ethics Committee of Beijing Anzhen Hospital and our hospital, oral consent was obtained at the beginning of data collection for this retrospective study instead of formal one. This study was performed in keeping with the requirements of the Declaration of Helsinki.
Not Applicable.

Competing interests

As AHA sponsor to this multi-center project, Pfizer bears no responsibility on the goals, execution, nor publication of the project. The authors are solely responsible for the design and conduct of this content, all study analyses, the manuscript performance, and its final contents. The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Kalra S, Kishor K, Batra A, Aggarwal S. Atrial fibillation in diabetes: need for cardiovigilance. J Pak Med Assoc. 2019;69:437–9.PubMed Kalra S, Kishor K, Batra A, Aggarwal S. Atrial fibillation in diabetes: need for cardiovigilance. J Pak Med Assoc. 2019;69:437–9.PubMed
2.
Zurück zum Zitat Li Y, et al. Risk factors for new-onset atrial fibrillation: a focus on Asian populations. Int J Cardiol. 2018;261:92–8.CrossRef Li Y, et al. Risk factors for new-onset atrial fibrillation: a focus on Asian populations. Int J Cardiol. 2018;261:92–8.CrossRef
3.
Zurück zum Zitat Chiang CE, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33:345–67.CrossRef Chiang CE, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33:345–67.CrossRef
4.
Zurück zum Zitat Baek YS, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc. 2017;6:6.CrossRef Baek YS, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc. 2017;6:6.CrossRef
5.
Zurück zum Zitat Karasoy D, et al. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace. 2013;15:781–6.CrossRef Karasoy D, et al. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace. 2013;15:781–6.CrossRef
6.
Zurück zum Zitat Kang SH, et al. Underweight is a risk factor for atrial fibrillation: a nationwide population-based study. Int J Cardiol. 2016;215:449–56.CrossRef Kang SH, et al. Underweight is a risk factor for atrial fibrillation: a nationwide population-based study. Int J Cardiol. 2016;215:449–56.CrossRef
7.
Zurück zum Zitat Zhang H, et al. Baseline characteristics and management of patients with atrial fibrillation/flutter in the emergency department: results of a prospective, multicentre registry in China. Intern Med J. 2014;44:742–8.CrossRef Zhang H, et al. Baseline characteristics and management of patients with atrial fibrillation/flutter in the emergency department: results of a prospective, multicentre registry in China. Intern Med J. 2014;44:742–8.CrossRef
8.
Zurück zum Zitat Xiong Q, et al. Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: the Nanchang atrial fibrillation project. Int J Cardiol. 2015;201:195–9.CrossRef Xiong Q, et al. Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: the Nanchang atrial fibrillation project. Int J Cardiol. 2015;201:195–9.CrossRef
9.
Zurück zum Zitat Ellrodt AG, et al. Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. Circulation. 2013;128:2447–60.CrossRef Ellrodt AG, et al. Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. Circulation. 2013;128:2447–60.CrossRef
10.
Zurück zum Zitat Hao Y, et al. Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open. 2018;8:e020968.CrossRef Hao Y, et al. Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation. BMJ Open. 2018;8:e020968.CrossRef
11.
Zurück zum Zitat McNamara RL, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing Commitee to develop data standards on atrial fibrillation). J Am Coll Cardiol. 2004;44:475–95.CrossRef McNamara RL, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing Commitee to develop data standards on atrial fibrillation). J Am Coll Cardiol. 2004;44:475–95.CrossRef
12.
Zurück zum Zitat Andrade JG, et al. Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC guidelines. Can J Cardiol. 2017;33:965–76.CrossRef Andrade JG, et al. Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC guidelines. Can J Cardiol. 2017;33:965–76.CrossRef
13.
Zurück zum Zitat Expert WHO. Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.CrossRef Expert WHO. Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.CrossRef
14.
Zurück zum Zitat Kirchhof P, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.CrossRef Kirchhof P, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.CrossRef
15.
Zurück zum Zitat Wang TJ, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471–7.CrossRef Wang TJ, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471–7.CrossRef
16.
Zurück zum Zitat Wilhelmsen LA, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med. 2001;250:382–9.CrossRef Wilhelmsen LA, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med. 2001;250:382–9.CrossRef
17.
Zurück zum Zitat Gao B, et al. Underweight but metabolically abnormal phenotype: metabolic features and its association with cardiovascular disease. Eur J Intern Med. 2016;29:46–51.CrossRef Gao B, et al. Underweight but metabolically abnormal phenotype: metabolic features and its association with cardiovascular disease. Eur J Intern Med. 2016;29:46–51.CrossRef
18.
Zurück zum Zitat Zehirlioglu L, et al. Cardiovascular risk, risk knowledge, and related factors in patients with type 2 diabetes. Clin Nurs Res. 2019;1054773819844070. Zehirlioglu L, et al. Cardiovascular risk, risk knowledge, and related factors in patients with type 2 diabetes. Clin Nurs Res. 2019;1054773819844070.
19.
Zurück zum Zitat Zhu W, et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: A meta-analysis and systematic review. J Am Heart Assoc. 2016;5:e004006. Zhu W, et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: A meta-analysis and systematic review. J Am Heart Assoc. 2016;5:e004006.
20.
Zurück zum Zitat Curtis JP, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55–61.CrossRef Curtis JP, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55–61.CrossRef
21.
Zurück zum Zitat Romero-Corral A, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368:666–78.CrossRef Romero-Corral A, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368:666–78.CrossRef
22.
Zurück zum Zitat Al-Rawahi M, Proietti R, Thanassoulis G. Pericardial fat and atrial fibrillation: epidemiology, mechanisms and interventions. Int J Cardiol. 2015;195:98–103.CrossRef Al-Rawahi M, Proietti R, Thanassoulis G. Pericardial fat and atrial fibrillation: epidemiology, mechanisms and interventions. Int J Cardiol. 2015;195:98–103.CrossRef
23.
Zurück zum Zitat Sanders P, Lau DH. Mortality paradox in obesity and atrial fibrillation: true clinical phenomenon or red herring in atrial fibrillation care? JACC Clin Electrophysiol. 2016;2:364–6.CrossRef Sanders P, Lau DH. Mortality paradox in obesity and atrial fibrillation: true clinical phenomenon or red herring in atrial fibrillation care? JACC Clin Electrophysiol. 2016;2:364–6.CrossRef
24.
Zurück zum Zitat Anaszewicz M, Budzyński J. Clinical significance of nutritional status in patients with atrial fibrillation: an overview of current evidence. J Cardiol. 2017;69(5):719–30.CrossRef Anaszewicz M, Budzyński J. Clinical significance of nutritional status in patients with atrial fibrillation: an overview of current evidence. J Cardiol. 2017;69(5):719–30.CrossRef
25.
Zurück zum Zitat Setayesh T, et al. Impact of obesity and overweight on DNA stability: few facts and many hypotheses. Mutat Res. 2018;777:64–91.CrossRef Setayesh T, et al. Impact of obesity and overweight on DNA stability: few facts and many hypotheses. Mutat Res. 2018;777:64–91.CrossRef
26.
Zurück zum Zitat Sung J, Ho CT, Wang Y. Preventive mechanism of bioactive dietary foods on obesity-related inflammation and diseases. Food Funct. 2018;9:6081–95.CrossRef Sung J, Ho CT, Wang Y. Preventive mechanism of bioactive dietary foods on obesity-related inflammation and diseases. Food Funct. 2018;9:6081–95.CrossRef
27.
Zurück zum Zitat Kizer NT, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011;117:948–56.CrossRef Kizer NT, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011;117:948–56.CrossRef
28.
Zurück zum Zitat Meyerhardt JA, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–95.CrossRef Meyerhardt JA, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–95.CrossRef
29.
Zurück zum Zitat Migita K, et al. Impact of being underweight on the long-term outcomes of patients with gastric cancer. Gastric Cancer. 2016;19:735–43.CrossRef Migita K, et al. Impact of being underweight on the long-term outcomes of patients with gastric cancer. Gastric Cancer. 2016;19:735–43.CrossRef
30.
Zurück zum Zitat Pandey A, et al. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry. JACC Clin Electrophysiol. 2016;2:355–63.CrossRef Pandey A, et al. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry. JACC Clin Electrophysiol. 2016;2:355–63.CrossRef
31.
Zurück zum Zitat Karmazyn M, et al. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res. 2008;79:279–86.CrossRef Karmazyn M, et al. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res. 2008;79:279–86.CrossRef
32.
Zurück zum Zitat Brúsik M, et al. Circulatory and adipose tissue leptin and adiponectin in relationship to resting energy expenditure in patients with chronic obstructive pulmonary disease. Physiol Res. 2012;61:469–80.CrossRef Brúsik M, et al. Circulatory and adipose tissue leptin and adiponectin in relationship to resting energy expenditure in patients with chronic obstructive pulmonary disease. Physiol Res. 2012;61:469–80.CrossRef
33.
Zurück zum Zitat Macheret F, et al. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart. 2015;101:1368–74.CrossRef Macheret F, et al. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart. 2015;101:1368–74.CrossRef
Metadaten
Titel
BMI differences among in-hospital management and outcomes in patients with atrial fibrillation: findings from the Care for Cardiovascular Disease project in China
verfasst von
Fuxue Deng
Yan Zhang
Qiang Zhao
Yangyang Deng
Shanshan Gao
Lisha Zhang
Mengya Dong
Zuyi Yuan
Xinjun Lei
on behalf of the CCC-AF investigators
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2020
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01544-8

Weitere Artikel der Ausgabe 1/2020

BMC Cardiovascular Disorders 1/2020 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.